Natural Product (NP) Details
General Information of the NP (ID: NP1431) | |||||
---|---|---|---|---|---|
Name |
Orientin
|
||||
Synonyms |
Orientin; 28608-75-5; Lutexin; Luteolin-8-glucoside; Luteolin 8-C-glucoside; UNII-IAX93XCW6C; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-8-beta-D-glucopyranosyl-5,7-dihydroxy-; 8-beta-D-glucosylluteolin; IAX93XCW6C; CHEBI:7781; MFCD00017432; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; Orientin (Flavone); 8-glucosylluteolin; Orientine; Luteolin-8-C-glucoside; Luteolin 8-C-beta-D-glucopyranoside; 2-(3,4-dihydroxyphenyl)-8-beta-D-glucopyranosyl-5,7-dihydroxy-4H-chromen-4-one; NSC-133101; 8-beta-D-Glucopyranosyl-3',4',5,7-tetrahydroxyflavone; 2-(3,4-Dihydroxyphenyl)-8-beta-D-glucopyranosyl-5,7-dihydroxy-4H-1-benzopyran-4-one; SCHEMBL25942; Orientin, analytical standard; CHEMBL520866; Orientin, >=97% (HPLC); BDBM84982; DTXSID60182790; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-8-.beta.-D-glucopyranosyl-5,7-dihydroxy-; HMS3886J16; HY-N0405; ZINC4098560; s9099; AKOS015896746; CCG-269214; AS-73888; CS-0008937; Y0149; A12096; C10114; 608O755; A819507; Orientin, primary pharmaceutical reference standard; Q421676; Q-100362; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; 2-[3,4-bis(oxidanyl)phenyl]-8-[(2S,3R,4R,5S,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]-5,7-bis(oxidanyl)chromen-4-one
Click to Show/Hide
|
||||
Species Origin | Ranunculaceae ... | Click to Show/Hide | |||
Ranunculaceae | |||||
Disease | Colorectal cancer [ICD-11: 2B91] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C21H20O11
|
||||
PubChem CID | |||||
Canonical SMILES |
C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4C(C(C(C(O4)CO)O)O)O)O)O
|
||||
InChI |
1S/C21H20O11/c22-6-14-17(28)18(29)19(30)21(32-14)16-11(26)4-10(25)15-12(27)5-13(31-20(15)16)7-1-2-8(23)9(24)3-7/h1-5,14,17-19,21-26,28-30H,6H2/t14-,17-,18+,19-,21+/m1/s1
|
||||
InChIKey |
PLAPMLGJVGLZOV-VPRICQMDSA-N
|
||||
CAS Number |
CAS 28608-75-5
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
BS21 | Obesity | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Phosphorylation | ACACA | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CEBPA | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CHPT1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | FABP4 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | FAS | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | PPAR-gamma | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PPARGC1A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PRDM16 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SREBF1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | UCP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | UCP2 | Molecule Info | |||
In-vitro Model | 3T3-L1 | CVCL_0123 | Healthy | Mus musculus | ||
Experimental
Result(s) |
BS21 plays a modulatory role in adipocytes by reducing adipogenesis and lipogenesis, increasing fat oxidation, and inducing browning. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Extracellular signal-regulated kinase 1 (ERK1) | Molecule Info | [3] | |
Extracellular signal-regulated kinase 2 (ERK2) | Molecule Info | [3] | ||
Stress-activated protein kinase JNK1 (JNK1) | Molecule Info | [3] | ||
Stress-activated protein kinase JNK2 (JNK2) | Molecule Info | [3] | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | Rap1 signaling pathway | |||
5 | cGMP-PKG signaling pathway | |||
6 | cAMP signaling pathway | |||
7 | Chemokine signaling pathway | |||
8 | HIF-1 signaling pathway | |||
9 | FoxO signaling pathway | |||
10 | Sphingolipid signaling pathway | |||
11 | Oocyte meiosis | |||
12 | mTOR signaling pathway | |||
13 | PI3K-Akt signaling pathway | |||
14 | Adrenergic signaling in cardiomyocytes | |||
15 | Vascular smooth muscle contraction | |||
16 | Dorso-ventral axis formation | |||
17 | TGF-beta signaling pathway | |||
18 | Axon guidance | |||
19 | VEGF signaling pathway | |||
20 | Osteoclast differentiation | |||
21 | Focal adhesion | |||
22 | Adherens junction | |||
23 | Gap junction | |||
24 | Signaling pathways regulating pluripotency of stem cells | |||
25 | Platelet activation | |||
26 | Toll-like receptor signaling pathway | |||
27 | NOD-like receptor signaling pathway | |||
28 | Natural killer cell mediated cytotoxicity | |||
29 | T cell receptor signaling pathway | |||
30 | B cell receptor signaling pathway | |||
31 | Fc epsilon RI signaling pathway | |||
32 | Fc gamma R-mediated phagocytosis | |||
33 | TNF signaling pathway | |||
34 | Circadian entrainment | |||
35 | Long-term potentiation | |||
36 | Neurotrophin signaling pathway | |||
37 | Retrograde endocannabinoid signaling | |||
38 | Glutamatergic synapse | |||
39 | Cholinergic synapse | |||
40 | Serotonergic synapse | |||
41 | Long-term depression | |||
42 | Regulation of actin cytoskeleton | |||
43 | Insulin signaling pathway | |||
44 | GnRH signaling pathway | |||
45 | Progesterone-mediated oocyte maturation | |||
46 | Estrogen signaling pathway | |||
47 | Melanogenesis | |||
48 | Prolactin signaling pathway | |||
49 | Thyroid hormone signaling pathway | |||
50 | Oxytocin signaling pathway | |||
51 | Type II diabetes mellitus | |||
52 | Aldosterone-regulated sodium reabsorption | |||
53 | Alzheimer's disease | |||
54 | Prion diseases | |||
55 | Alcoholism | |||
56 | Shigellosis | |||
57 | Salmonella infection | |||
58 | Pertussis | |||
59 | Leishmaniasis | |||
60 | Chagas disease (American trypanosomiasis) | |||
61 | Toxoplasmosis | |||
62 | Tuberculosis | |||
63 | Hepatitis C | |||
64 | Hepatitis B | |||
65 | Influenza A | |||
66 | Pathways in cancer | |||
67 | Viral carcinogenesis | |||
68 | Proteoglycans in cancer | |||
69 | Colorectal cancer | |||
70 | Renal cell carcinoma | |||
71 | Pancreatic cancer | |||
72 | Endometrial cancer | |||
73 | Glioma | |||
74 | Prostate cancer | |||
75 | Thyroid cancer | |||
76 | Melanoma | |||
77 | Bladder cancer | |||
78 | Chronic myeloid leukemia | |||
79 | Acute myeloid leukemia | |||
80 | Non-small cell lung cancer | |||
81 | Central carbon metabolism in cancer | |||
82 | Choline metabolism in cancer | |||
83 | Protein processing in endoplasmic reticulum | |||
84 | Wnt signaling pathway | |||
85 | RIG-I-like receptor signaling pathway | |||
86 | Dopaminergic synapse | |||
87 | Inflammatory mediator regulation of TRP channels | |||
88 | Adipocytokine signaling pathway | |||
89 | Non-alcoholic fatty liver disease (NAFLD) | |||
90 | Epithelial cell signaling in Helicobacter pylori infection | |||
91 | HTLV-I infection | |||
92 | Herpes simplex infection | |||
93 | Epstein-Barr virus infection | |||
94 | MicroRNAs in cancer | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
2 | TCR Signaling Pathway | |||
3 | TNFalpha Signaling Pathway | |||
4 | IL2 Signaling Pathway | |||
Panther Pathway | Alzheimer disease-amyloid secretase pathway | Click to Show/Hide | ||
2 | Angiogenesis | |||
3 | Apoptosis signaling pathway | |||
4 | B cell activation | |||
5 | EGF receptor signaling pathway | |||
6 | Endothelin signaling pathway | |||
7 | FGF signaling pathway | |||
8 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
9 | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | |||
10 | Integrin signalling pathway | |||
11 | Interferon-gamma signaling pathway | |||
12 | Interleukin signaling pathway | |||
13 | PDGF signaling pathway | |||
14 | Parkinson disease | |||
15 | TGF-beta signaling pathway | |||
16 | T cell activation | |||
17 | Toll receptor signaling pathway | |||
18 | VEGF signaling pathway | |||
19 | Ras Pathway | |||
20 | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
21 | CCKR signaling map ST | |||
22 | FAS signaling pathway | |||
23 | Oxidative stress response | |||
24 | Huntington disease | |||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
3 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
4 | Insulin Signalling | |||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
2 | Endothelins | |||
3 | BCR signaling pathway | |||
4 | Signaling events mediated by PRL | |||
5 | ErbB4 signaling events | |||
6 | GMCSF-mediated signaling events | |||
7 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
8 | S1P3 pathway | |||
9 | EPHB forward signaling | |||
10 | Osteopontin-mediated events | |||
11 | S1P4 pathway | |||
12 | Presenilin action in Notch and Wnt signaling | |||
13 | TRAIL signaling pathway | |||
14 | CDC42 signaling events | |||
15 | Signaling events regulated by Ret tyrosine kinase | |||
16 | Angiopoietin receptor Tie2-mediated signaling | |||
17 | S1P1 pathway | |||
18 | Regulation of Telomerase | |||
19 | Netrin-mediated signaling events | |||
20 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
21 | Glucocorticoid receptor regulatory network | |||
22 | Arf6 downstream pathway | |||
23 | mTOR signaling pathway | |||
24 | IL2-mediated signaling events | |||
25 | EGF receptor (ErbB1) signaling pathway | |||
26 | Ras signaling in the CD4+ TCR pathway | |||
27 | Ceramide signaling pathway | |||
28 | Integrins in angiogenesis | |||
29 | IFN-gamma pathway | |||
30 | ErbB1 downstream signaling | |||
31 | ATF-2 transcription factor network | |||
32 | ErbB2/ErbB3 signaling events | |||
33 | ALK1 signaling events | |||
34 | PDGFR-beta signaling pathway | |||
35 | Neurotrophic factor-mediated Trk receptor signaling | |||
36 | Syndecan-1-mediated signaling events | |||
37 | Retinoic acid receptors-mediated signaling | |||
38 | Nongenotropic Androgen signaling | |||
39 | CXCR3-mediated signaling events | |||
40 | VEGFR1 specific signals | |||
41 | Regulation of cytoplasmic and nuclear SMAD2/3 signaling | |||
42 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
43 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
44 | Syndecan-2-mediated signaling events | |||
45 | Cellular roles of Anthrax toxin | |||
46 | S1P2 pathway | |||
47 | Trk receptor signaling mediated by the MAPK pathway | |||
48 | Downstream signaling in naï | |||
49 | ||||
50 | VEGFR3 signaling in lymphatic endothelium | |||
51 | Alpha-synuclein signaling | |||
52 | FGF signaling pathway | |||
53 | RhoA signaling pathway | |||
54 | Noncanonical Wnt signaling pathway | |||
55 | CD40/CD40L signaling | |||
56 | Reelin signaling pathway | |||
57 | FAS (CD95) signaling pathway | |||
58 | IL1-mediated signaling events | |||
59 | Rapid glucocorticoid signaling | |||
60 | FoxO family signaling | |||
61 | Regulation of Androgen receptor activity | |||
62 | p75(NTR)-mediated signaling | |||
63 | JNK signaling in the CD4+ TCR pathway | |||
64 | Nephrin/Neph1 signaling in the kidney podocyte | |||
65 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
66 | EPO signaling pathway | |||
67 | Ephrin B reverse signaling | |||
68 | p53 pathway | |||
69 | N-cadherin signaling events | |||
70 | RAC1 signaling pathway | |||
71 | Signaling events mediated by focal adhesion kinase | |||
72 | Glypican 3 network | |||
73 | IL12 signaling mediated by STAT4 | |||
74 | Class IB PI3K non-lipid kinase events | |||
75 | BMP receptor signaling | |||
76 | Regulation of retinoblastoma protein | |||
Reactome | MAPK3 (ERK1) activation | Click to Show/Hide | ||
2 | RAF-independent MAPK1/3 activation | |||
3 | ISG15 antiviral mechanism | |||
4 | ERK/MAPK targets | |||
5 | Regulation of actin dynamics for phagocytic cup formation | |||
6 | Oxidative Stress Induced Senescence | |||
7 | Senescence-Associated Secretory Phenotype (SASP) | |||
8 | Oncogene Induced Senescence | |||
9 | FCERI mediated MAPK activation | |||
10 | Regulation of HSF1-mediated heat shock response | |||
11 | NCAM signaling for neurite out-growth | |||
12 | Activation of the AP-1 family of transcription factors | |||
13 | Thrombin signalling through proteinase activated receptors (PARs) | |||
14 | Negative regulation of FGFR1 signaling | |||
15 | Negative regulation of FGFR2 signaling | |||
16 | Negative regulation of FGFR3 signaling | |||
17 | Negative regulation of FGFR4 signaling | |||
18 | RHO GTPases Activate WASPs and WAVEs | |||
19 | RAF/MAP kinase cascade | |||
20 | MAP2K and MAPK activation | |||
21 | Negative feedback regulation of MAPK pathway | |||
22 | Negative regulation of MAPK pathway | |||
23 | Signal attenuation | |||
24 | Advanced glycosylation endproduct receptor signaling | |||
25 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
26 | Growth hormone receptor signaling | |||
27 | NRAGE signals death through JNK | |||
28 | NRIF signals cell death from the nucleus | |||
29 | DSCAM interactions | |||
30 | JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | |||
31 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||
32 | MAPK1 (ERK2) activation | |||
33 | Golgi Cisternae Pericentriolar Stack Reorganization | |||
34 | Recycling pathway of L1 | |||
35 | CREB phosphorylation through the activation of Ras | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
3 | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
4 | Serotonin HTR1 Group and FOS Pathway | |||
5 | TCR Signaling Pathway | |||
6 | Hypothetical Network for Drug Addiction | |||
7 | EPO Receptor Signaling | |||
8 | TGF Beta Signaling Pathway | |||
9 | Regulation of Actin Cytoskeleton | |||
10 | IL-2 Signaling Pathway | |||
11 | Insulin Signaling | |||
12 | MAPK Cascade | |||
13 | IL-4 Signaling Pathway | |||
14 | MAPK Signaling Pathway | |||
15 | IL-6 signaling pathway | |||
16 | Signaling of Hepatocyte Growth Factor Receptor | |||
17 | Kit receptor signaling pathway | |||
18 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
19 | IL-3 Signaling Pathway | |||
20 | Cardiac Hypertrophic Response | |||
21 | MAP kinase activation in TLR cascade | |||
22 | Fc epsilon receptor (FCERI) signaling | |||
23 | RAF/MAP kinase cascade | |||
24 | Structural Pathway of Interleukin 1 (IL-1) | |||
25 | Genes and (Common) Pathways Underlying Drug Addiction | |||
26 | Signal Transduction of S1P Receptor | |||
27 | PDGF Pathway | |||
28 | Alpha 6 Beta 4 signaling pathway | |||
29 | Spinal Cord Injury | |||
30 | BDNF signaling pathway | |||
31 | Integrated Pancreatic Cancer Pathway | |||
32 | Oncostatin M Signaling Pathway | |||
33 | Corticotropin-releasing hormone | |||
34 | Interleukin-11 Signaling Pathway | |||
35 | AGE/RAGE pathway | |||
36 | TNF alpha Signaling Pathway | |||
37 | Prostate Cancer | |||
38 | Signaling Pathways in Glioblastoma | |||
39 | TSLP Signaling Pathway | |||
40 | IL-9 Signaling Pathway | |||
41 | IL17 signaling pathway | |||
42 | Alzheimers Disease | |||
43 | IL-7 Signaling Pathway | |||
44 | TWEAK Signaling Pathway | |||
45 | FSH signaling pathway | |||
46 | Leptin signaling pathway | |||
47 | RANKL/RANK Signaling Pathway | |||
48 | IL-1 signaling pathway | |||
49 | Thrombin signalling through proteinase activated receptors (PARs) | |||
50 | Signaling by Insulin receptor | |||
51 | Signaling by FGFR | |||
52 | RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | |||
53 | L1CAM interactions | |||
54 | Advanced glycosylation endproduct receptor signaling | |||
55 | Apoptosis Modulation and Signaling | |||
56 | MicroRNAs in cardiomyocyte hypertrophy | |||
57 | Regulation of toll-like receptor signaling pathway | |||
58 | Osteopontin Signaling | |||
59 | IL-5 Signaling Pathway | |||
60 | DNA Damage Response (only ATM dependent) | |||
61 | ErbB Signaling Pathway | |||
62 | EGF/EGFR Signaling Pathway | |||
63 | TGF beta Signaling Pathway | |||
64 | FAS pathway and Stress induction of HSP regulation | |||
65 | Transcriptional activation by NRF2 | |||
66 | NLR Proteins | |||
67 | Nanoparticle-mediated activation of receptor signaling | |||
68 | EBV LMP1 signaling | |||
69 | JAK/STAT | |||
70 | Nanoparticle triggered regulated necrosis | |||
71 | B Cell Receptor Signaling Pathway | |||
72 | Signalling by NGF | |||
73 | Intrinsic Pathway for Apoptosis | |||
74 | DSCAM interactions | |||
75 | Type II diabetes mellitus | |||
76 | Physiological and Pathological Hypertrophy of the Heart | |||
77 | Osteoclast Signaling | |||
78 | Vitamin A and Carotenoid Metabolism | |||
79 | Senescence and Autophagy in Cancer | |||
80 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
81 | Bladder Cancer | |||
82 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
83 | Nifedipine Activity | |||
84 | Aryl Hydrocarbon Receptor | |||
85 | Endothelin Pathways | |||
86 | Integrated Breast Cancer Pathway | |||
87 | Opioid Signalling | |||
88 | Integrin-mediated Cell Adhesion | |||
89 | Heart Development | |||
90 | Angiogenesis | |||
91 | Wnt Signaling Pathway | |||
92 | Wnt Signaling Pathway and Pluripotency | |||
93 | ATM Signaling Pathway |